Tharimmune executive chairman buys $500,000 in shares

Published 24/06/2025, 02:36
Tharimmune executive chairman buys $500,000 in shares

Gravitas Capital LP, Executive Chairman at Tharimmune, Inc. (NASDAQ:THAR), has recently purchased 337,838 shares of common stock at a price of $1.48, according to a Form 4 filing with the Securities and Exchange Commission. The transaction, which occurred on June 20, 2025, amounted to $500,000. The purchase price represents a 13% premium to the current trading price of $1.31. According to InvestingPro data, the stock has declined 9% in the past week, with the company’s market capitalization now standing at $3.6 million.

Following the transaction, Gravitas Capital LP directly owns 732,424 shares of Tharimmune. InvestingPro analysis shows the company maintains a positive cash-to-debt position, though its overall financial health score is rated as weak. Subscribers can access 8 additional ProTips and comprehensive financial metrics for deeper insight into THAR’s performance.

In other recent news, Tharimmune, Inc. has announced several significant developments. The company released promising results from its Phase 1 study of TH104, a drug designed for opioid exposure prophylaxis, which showed a distinct metabolic profile and comparable safety to existing treatments. The FDA’s positive feedback suggests Tharimmune might submit a New Drug Application without further clinical trials. Additionally, Tharimmune has made notable executive changes, appointing Sireesh Appajosyula as CEO and Vincent LoPriore as Executive Chairman. These changes come alongside the departure of former CEO Randy Milby, who stepped down for personal reasons, with a settlement agreement in place. The company has also expanded its Board of Directors, adding Clay Kahler and Gary Stetz, as it prepares for upcoming strategic growth phases. These appointments reflect Tharimmune’s focus on enhancing its leadership and governance as it advances its clinical programs. Tharimmune continues to develop a diverse pipeline, including treatments for autoimmune diseases and a multispecific biologic platform targeting solid tumors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.